The ability of RANKL, together with other factors such as TNF-α [23], to rescue osteoclasts from the pro-apoptotic effects of BPs may account for the apparent lack of effectiveness of BPs (particularly the less potent BPs such as CLO and ALN) in preventing local, inflammation-induced bone loss in RA. This evidence concerns the gene TNFSF11 and rheumatoid arthritis.